Adjuvant durvalumab therapy improves survival in limited-stage small cell lung cancer
1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo ...
Tag: lung cancer
Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
#VisualAbstract Telehealth vs In-Person Early Palliative Care for Patients with Advanced Lung Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
TKI With or Without SRS for Brain Metastases From EGFR/ALK Mutated NSCLC
1. Median overall survival was 41 months in the TKI-only group vs 40 months in the TKI-SRS group, with HR ...
AstraZeneca’s Tagrisso and chemotherapy pairing have been approved in Canada for treatment in locally advanced or metastatic non-small cell lung cancer.
Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution ...
Johnson and Johnson: The subcutaneous formulation of Rybrevant was more effective than the intravenous formulation in reducing the risk of death in lung cancer patients.
The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination ...
#VisualAbstract Amivantamab-lazertinib is Effective for Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Amivantamab plus Lazertinib Improves Outcomes in Previously Untreated EGFR-Mutated Advanced NSCLC
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
Click to read the study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
